Novorapid (Insulin Aspart)

Insulin aspart, the active ingredient in Novorapid, is a rapid‑acting insulin analog presented as a clear solution for subcutaneous injection use. It is employed to manage hyperglycemia in diabetes mellitus, providing fast post‑prandial glucose control for adults and children requiring insulin therapy. It is formulated in a cartridge or vial for use with insulin pens or syringes, and its onset of action occurs within minutes after injection.

GNH USA supplies Novorapid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides reliable logistics and regulatory support to pharmacies, clinics and procurement teams across multiple continents.

Novorapid (insulin aspart) is a rapid‑acting insulin analog used to control blood glucose in diabetes mellitus. - Type 1 diabetes mellitus: provides mealtime insulin to reduce post‑prandial hyperglycemia. - Type 2 diabetes mellitus: used in basal‑bolus regimens for precise glucose control around meals. - Gestational diabetes: offers rapid glucose lowering when oral agents are insufficient. - Insulin pump therapy: serves as a rapid‑acting component for continuous subcutaneous insulin infusion.

Novorapid may cause a range of adverse reactions, from common to serious. Common Side Effects: - Hypoglycemia: low blood glucose levels, especially if meals are delayed or missed. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight with prolonged insulin use. - Lipodystrophy: localized thickening or loss of subcutaneous fat at injection sites. Serious or Rare Side Effects: - Severe hypoglycemia: neurological symptoms or loss of consciousness requiring assistance. - Allergic reactions: rash, urticaria, or anaphylaxis in sensitive individuals. - Edema: abnormal fluid retention leading to swelling of extremities.

When using Novorapid, several precautions should be observed to ensure safety and efficacy. - Monitor blood glucose: check levels before meals and adjust dose as directed. - Adjust for renal or hepatic impairment: reduced clearance may increase hypoglycemia risk. - Avoid alcohol excess: can potentiate insulin’s glucose‑lowering effect. - Use with caution in the elderly: heightened sensitivity to hypoglycemia. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Novorapid can interact with other medicines, altering its glucose‑lowering effect or safety profile. Major Interactions (Avoid): - Sulfonylureas or meglitinides: combined use markedly increases hypoglycemia risk. - Beta‑blockers: may mask symptoms of hypoglycemia, complicating detection. - Alcohol: can cause unpredictable drops in blood glucose when combined with insulin. Moderate Interactions (Monitor Closely): - ACE inhibitors and ARBs: may enhance insulin sensitivity, requiring dose adjustment. - Thiazide diuretics: can raise blood glucose, potentially reducing insulin effectiveness. - Corticosteroids: may increase glucose levels, necessitating higher insulin doses.